After Mylan created a firestorm with huge price increases for its anti-allergy EpiPen, it's now set to have a competitor in 2017.
NPR reports small, privately-held pharmaceutical company Kaleo plans to bring its epinephrine auto-injector Auvi-Q back to the market next year. It had been pulled by Sanofi over dosage problems in 2015, and Kaleo then bought back the rights to the device in February.
Kaleo founder Eric Edwards told NPR the issues with delivering a reliable dose of epinephrine have been fixed.
While Auvi-Q would provide an alternative to customers frustrated with the 400 percent hike in EpiPen prices since Mylan acquired the device, Edwards wouldn’t say how much Paleo would charge for it. In fact, the company may replicate Mylan’s sale strategy to maximize payments from insurers.
To read more, click on the link below:
John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.